



## Development of Novel Drugs for Alzheimer's Disease and Myasthenia Gravis

Guest Editors:

**Prof. Dr. Kamil Kuca**

Department of Chemistry,  
Faculty of Science, University of  
Hradec Kralove, Hradec Kralove,  
Czech Republic

**Dr. Martin Valis**

Neurology Clinic, University  
Hospital Hradec Kralove, Hradec  
Kralove, Czech Republic

**Dr. Eugenie Nepovimova**

Department of Chemistry,  
Faculty of Science, University of  
Hradec Králové, 50003 Hradec  
Králové, Czech Republic

Deadline for manuscript  
submissions:

**closed (5 April 2020)**

### Message from the Guest Editors

Searching for novel drugs for the treatment of Alzheimer's disease (AD) became a main task of current developed societies. There were/are and will be novel drug candidates designed, synthesized and tested throughout many places of the world. Despite tremendous advances in understanding many aspects of AD pathogenesis, there are no proven disease-modifying therapies and the only available ones are minimally effective symptomatic therapies.

Myasthenia gravis (MG) is a neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles. In the case of this disease, efficacy of currently-available drugs is limited.

Both diseases (AD and MG) are associated with an enzyme acetylcholinesterase (AChE), which is a target for development on novel drug candidates for these diseases.

In this Special Issue of *International Journal of Molecular Sciences*, we would like to discuss all chemico-biological aspects, which are behind the Alzheimer's disease, as well as Myasthenia gravis.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Maurizio Battino

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

## Contact Us

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI